HERMES-ASSET-MANAGEMENT
In the “Crypto Valley” of Zug, the world’s capital of crypto currencies and blockchain, the Crypto Currency Index (CCI30) has been presented to the public. Comprised of the 30 crypto currencies with the biggest market capitalization, the CCI30 is the first index of its kind to track the booming crypto currency marketplace. Its constituent currencies represent 93% of the world’s total crypto currencies market cap.
The mathematical models that power the index – think of it as an S&P 500 for crypto currencies – were created by a team of prizewinning mathematics PhDs, quantitative analysts and traders, led by Igor Rivin, Professor of Mathematics at Temple University, until recently Regius Professor of Mathematics at St. Andrews University, and Carlo Scevola, economist and investor, director of Hermes Asset Management.
“Keynesian economic policies have eroded the public’s faith in ‘fiat money’ such as dollars and euros,” said Scevola, who runs a financial advisory firm. “Crypto currencies are filling a void, and our index will help investors gain insights into this exploding marketplace.”
Scevola continued: “This is the first crypto currencies index that can be used as an actual investment tool, not just an academic curiosity or a marketing gimmick. Despite our strong theoretical background, we didn’t forget that we are first of all investors and traders, and as such we wanted and needed an index that has a practical use. It is set to be the benchmark for this sector, and it will be widely adopted by investment funds and ETFs.”
The influx of traders moving into crypto currencies has contributed to an eightfold rise in valuations since the beginning of 2017. Concerned that stocks prices may have plateaued, investors increasingly are plowing money into crypto currencies, a largely untapped market that until recently has been the realm of professional traders.
While Bitcoin is the best known crypto currency, many others have come online. Crypto currencies now have a combined market capitalization of around $150 billion at the time of this writing. According to a report on CNBC, the daily trading volume of these crypto currencies could surpass that of Apple (more than $6 billion) in the near future.
Calculating the Index
“Crypto currency market caps can be quite volatile,” said Professor Rivin, an award-winning mathematician and theoretical economist. “Thus the ‘top 30’ have to be computed much more frequently than, say, the constituents of the FTSE 100.”
Given the volatility of the space, the CCI30 performs a full computation of its constituents every quarter, and reweighs the constituents monthly. In addition, rather than compute the top thirty crypto currencies based on a single day’s market cap, the CCI30 will smooth its data by using a weighted average of the past month.
Crypto Currency Index data is available free of charge to the general public, updated in real time on the website www.cci30.com .
Those wishing to take advantage of the crypto currency marketplace will shortly have the opportunity to invest in the new Cryptos Fund, which will passively replicate the CCI30.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171016005135/en/
Contact:
Media:
Hermes Asset Management
Carlo Scevola, +41.445.853.445
info@cci30.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
30 Peer-Reviewed Studies Highlight Statistically Significant Health Benefits of Almased16.7.2025 09:15:00 CEST | Press release
Two recent, peer-reviewed clinical studies have found that Almased, a high-protein, low-glycemic meal replacement, delivers significant health benefits ranging from weight loss and improved metabolic health to anti-aging effects and enhanced quality of life. Both reviews synthesize 30 peer-reviewed clinical studies across three decades of scientific research, confirming that Almased is effective and safe for weight reduction, preservation of lean muscle mass, and cardiovascular health. The 2025 review in the American Journal of Biomedical Science & Research highlighted Almased’s efficacy and safety for wide groups of people including individuals seeking weight loss, those with metabolic syndrome or fatty liver, older adults needing to preserve muscle mass, and athletes or healthy-weight individuals who require additional high-quality protein. This review also discusses how Almased’s patented fermentation process produces over 80 bioactive peptides, including 2 times the average daily i
The Future of Connectivity Starts Here: Network X Returns to Paris October 14 - 1616.7.2025 09:00:00 CEST | Press release
Show Reconvenes at Paris Expo Porte de Versailles with Global Representation of Industry Leaders and Telco Experts Network X 2025 - the only event that brings the fixed and mobile markets together - returns to Paris Expo Porte de Versailles October 14 - 16. Built for telecom's top players, this annual show drives business model innovation and monetisation of next-generation fixed, mobile, satellite and transport networks through AI and cloud. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716595903/en/ Speaker on Headliners Stage at Network X 2024 New to Network X in 2025 are specialty events designed to deliver expert insights on trending topics including Data Center World and two Expo Stages for Fixed-Line and Mobile. More than 5,500 telco network infrastructure professionals will gather alongside 1,500 telcos to learn from six program tracks highlighting the latest advancements in Fibre, Wi-Fi Networks and Services, IP
Skechers AERO Series Opens New Chapter of Technical Running Innovation16.7.2025 09:00:00 CEST | Press release
New Collection Features an Evolution in Design that Cuts Through the Wind for That Aerodynamic Feel on Every Run Skechers Performance opens a new chapter of running innovation with the arrival of the Skechers AERO series. Named for the aerodynamic feel of the design, Skechers AERO represents the latest evolution of technical running shoes from the brand. The collection is engineered to deliver an exhilarating blend of speed, style and comfort to help runners cut through the wind and push beyond their personal bests while logging miles. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250716754749/en/ Introducing the Skechers AERO Series of technical running shoes: Skechers AERO Burst, Skechers AERO Spark, and Skechers AERO Tempo (L-R). “Recently launched in North America and Asia, the AERO Series leverages innovative technologies to elevate our signature comfort that’s now available to runners in Europe,” said Ben Stewart, Vic
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom